Results 1 to 10 of about 151 (117)
The competitive inhibition of tissue transglutaminase by α-difluoromethylornithine [PDF]
FEBS Letters, 1984 The transglutaminase‐mediated insertion of putrescine into casein was inhibited competitively by α‐difluoromethylornithine (α‐DFMO), an enzyme‐activated irreversible inhibitor of ornithine decarboxylase. Preincubation of the amine acceptor (casein) or the enzyme itself with the inhibitor did not affect enzyme activity.
Jean-Guy Delcros +2 more
exaly +3 more sources
Frontiers in Chemistry, 2021 Targeting the polyamine biosynthetic pathway by inhibiting ornithine decarboxylase (ODC) is a powerful approach in the fight against diverse viruses, including SARS-CoV-2.
Joanna Bojarska +8 more
doaj +1 more source
Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells
Medical Sciences, 2022 Ovarian cancer accounts for 3% of the total cancers in women, yet it is the fifth leading cause of cancer deaths among women. The BRCA1/2 germline and somatic mutations confer a deficiency of the homologous recombination (HR) repair pathway.
Olivia El Naggar +3 more
doaj +1 more source
Medical Sciences, 2022 Polyamine biosynthesis is frequently dysregulated in cancers, and enhanced flux increases intracellular polyamines necessary for promoting cell growth, proliferation, and function.
Alexander Chin +3 more
doaj +1 more source
Difluoromethylornithine (DFMO) and Neuroblastoma: A Review
Cureus, 2023 Neuroblastoma is a type of cancer that affects the sympathetic nervous system and is the most common extracranial solid tumor in children. Difluoromethylornithine (DFMO) is a drug that has shown promise as a treatment option for high-risk neuroblastoma.
Tangella, Adarsh Vardhan +3 more
openaire +2 more sources
Difluoromethylornithine: The Proof Is in the Polyamines [PDF]
Cancer Prevention Research, 2012 AbstractIn this issue (beginning on page 1368), Kreul and colleagues report a retrospective review of long-term efficacy and toxicity for subjects participating in a phase III study of difluoromethylornithine (DFMO) for prevention of nonmelanoma skin cancer (NMSC).
Joanne M, Jeter, David S, Alberts
openaire +2 more sources
Difluoromethylornithine rebalances aberrant polyamine ratios in Snyder–Robinson syndrome
EMBO Molecular Medicine, 2023 Snyder–Robinson syndrome (SRS) results from mutations in spermine synthase (SMS), which converts the polyamine spermidine into spermine. Affecting primarily males, common manifestations of SRS include intellectual disability, osteoporosis, hypotonia, and
Tracy Murray Stewart +8 more
doaj +1 more source
Difluoromethylornithine (DFMO) and AMXT 1501 inhibit capsule biosynthesis in pneumococci
Scientific Reports, 2022 Polyamines are small cationic molecules that have been linked to various cellular processes including replication, translation, stress response and recently, capsule regulation in Streptococcus pneumoniae (Spn, pneumococcus).
Moses B. Ayoola +7 more
doaj +1 more source
Characterization of the Ototoxicity of Difluoromethylornithine and Its Enantiomers [PDF]
Toxicological Sciences, 2000 Difluoromethylornithine (DFMO) is an irreversible inhibitor of ornithine decarboxylase (ODC), the essential enzyme in mammalian polyamine biosynthesis (Pasic et al., 1997, Arch. Otolaryngol. Head Neck Surg. 123[12], 1281-1286). This cancer chemotherapeutic agent has significant ototoxic potential. Because the DFMO enantiomers differ in their ability to
M L, McWilliams, G D, Chen, L D, Fechter
openaire +2 more sources
Convenient Synthesis of α-Difluoromethylornithine [PDF]
Bioscience, Biotechnology, and Biochemistry, 1993 (1993). Convenient Synthesis of α-Difluoromethylornithine. Bioscience, Biotechnology, and Biochemistry: Vol. 57, No. 6, pp. 1024-1025.
Masahiko Seki +2 more
openaire +1 more source